Literature DB >> 23548600

Atorvastatin improves cognitive, emotional and motor impairments induced by intranasal 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) administration in rats, an experimental model of Parkinson's disease.

Adalberto A Castro1, Bárbara P Wiemes, Filipe C Matheus, Fernanda R Lapa, Giordano G Viola, Adair R Santos, Carla I Tasca, Rui D Prediger.   

Abstract

Affective disorders and memory impairments precede the classical motor symptoms seen in Parkinson's disease (PD) and the currently approved antiparkinsonian agents do not alleviate the non-motor symptoms as well as the underlying dopaminergic neuron degeneration. On the other hand, there is increasing evidence that inflammation plays a key role in the pathophysiology of PD and that the anti-inflammatory actions of statins are related to their neuroprotective properties against different insults in the CNS. The present data indicates that the oral treatment with atorvastatin (10mg/kg/day), once a day during 7 consecutive days, was able to prevent short-term memory impairments and depressive-like behavior of rats assessed in the social recognition and forced swimming tests at 7 and 14 days, respectively, after a single intranasal (i.n.) administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) (1mg/nostril). Importantly, at this time no significant alterations on the locomotor activity of the animals were observed in the open field test. Moreover, atorvastatin was found to protect against the long-lasting motor deficits evaluated in activity chambers and the loss of dopaminergic neurons in the substantia nigra pars compacta observed at 21 days after i.n. MPTP administration. At this time, despite the absence of spatial memory deficits in the water maze and in concentrations of the cytokines TNF-α, IL-1β and IL-10 in striatum and hippocampus following i.n. MPTP administration, atorvastatin treatment resulted in a significant increase in the striatal and hippocampal levels of nerve growth factor (NGF). These findings reinforce and extend the notion of the neuroprotective potential of atorvastatin and suggest that it may represent a new therapeutic tool for the management of motor and non-motor symptoms of PD.
Copyright © 2013 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23548600     DOI: 10.1016/j.brainres.2013.03.029

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  19 in total

1.  Atorvastatin and Fluoxetine Prevent Oxidative Stress and Mitochondrial Dysfunction Evoked by Glutamate Toxicity in Hippocampal Slices.

Authors:  Fabiana K Ludka; Tharine Dal-Cim; Luisa Bandeira Binder; Leandra Celso Constantino; Caio Massari; Carla I Tasca
Journal:  Mol Neurobiol       Date:  2016-04-06       Impact factor: 5.590

2.  The Gender-Biased Effects of Intranasal MPTP Administration on Anhedonic- and Depressive-Like Behaviors in C57BL/6 Mice: the Role of Neurotrophic Factors.

Authors:  Marissa Giovanna Schamne; Josiel Mileno Mack; Morgana Moretti; Filipe Carvalho Matheus; Roger Walz; Laurence Lanfumey; Rui Daniel Prediger
Journal:  Neurotox Res       Date:  2018-05-28       Impact factor: 3.911

3.  Influence of intranasal exposure of MPTP in multiple doses on liver functions and transition from non-motor to motor symptoms in a rat PD model.

Authors:  Indrani Datta; S R Mekha; Alka Kaushal; Kavina Ganapathy; Rema Razdan
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2019-08-29       Impact factor: 3.000

4.  Atorvastatin Prevents Early Oxidative Events and Modulates Inflammatory Mediators in the Striatum Following Intranasal 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) Administration in Rats.

Authors:  Naiani F Marques; Adalberto A Castro; Gianni Mancini; Fernanda L Rocha; Adair R S Santos; Rui D Prediger; Andreza Fabro De Bem; Carla I Tasca
Journal:  Neurotox Res       Date:  2017-11-21       Impact factor: 3.911

5.  Succinobucol, a Non-Statin Hypocholesterolemic Drug, Prevents Premotor Symptoms and Nigrostriatal Neurodegeneration in an Experimental Model of Parkinson's Disease.

Authors:  Danúbia Bonfanti Santos; Dirleise Colle; Eduardo Luiz Gasnhar Moreira; Mariana Appel Hort; Marcelo Godoi; Gael Le Douaron; Antonio Luiz Braga; Jamil Assreuy; Patrick Pierre Michel; Rui Daniel Prediger; Rita Raisman-Vozari; Marcelo Farina
Journal:  Mol Neurobiol       Date:  2016-02-06       Impact factor: 5.590

6.  MPP+-Lesioned Mice: an Experimental Model of Motor, Emotional, Memory/Learning, and Striatal Neurochemical Dysfunctions.

Authors:  Mauricio P Cunha; Francis L Pazini; Vicente Lieberknecht; Josiane Budni; Ágatha Oliveira; Júlia M Rosa; Gianni Mancini; Leidiane Mazzardo; André R Colla; Marina C Leite; Adair R S Santos; Daniel F Martins; Andreza F de Bem; Carlos Alberto S Gonçalves; Marcelo Farina; Ana Lúcia S Rodrigues
Journal:  Mol Neurobiol       Date:  2016-10-08       Impact factor: 5.590

7.  Effects of Agmatine on Depressive-Like Behavior Induced by Intracerebroventricular Administration of 1-Methyl-4-phenylpyridinium (MPP(+)).

Authors:  Morgana Moretti; Vivian Binder Neis; Filipe Carvalho Matheus; Mauricio Peña Cunha; Priscila Batista Rosa; Camille Mertins Ribeiro; Ana Lúcia S Rodrigues; Rui Daniel Prediger
Journal:  Neurotox Res       Date:  2015-07-09       Impact factor: 3.911

8.  Executive function deficits and glutamatergic protein alterations in a progressive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease.

Authors:  Lacey Pflibsen; Katherine A Stang; Michelle D Sconce; Vanessa B Wilson; Rebecca L Hood; Charles K Meshul; Suzanne H Mitchell
Journal:  J Neurosci Res       Date:  2015-08-31       Impact factor: 4.164

9.  Atorvastatin Attenuates Cognitive Deficits and Neuroinflammation Induced by Aβ1-42 Involving Modulation of TLR4/TRAF6/NF-κB Pathway.

Authors:  Shan Wang; Xiaowei Zhang; Liuyu Zhai; Xiaona Sheng; Weina Zheng; Hongshan Chu; Guohua Zhang
Journal:  J Mol Neurosci       Date:  2018-02-07       Impact factor: 3.444

Review 10.  Neuroinflammation in neurological disorders: pharmacotherapeutic targets from bench to bedside.

Authors:  Awanish Mishra; Ritam Bandopadhyay; Prabhakar Kumar Singh; Pragya Shakti Mishra; Neha Sharma; Navneet Khurana
Journal:  Metab Brain Dis       Date:  2021-08-13       Impact factor: 3.584

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.